Roche plans to collaborate with Ibex Medical Analytics and Amazon Web Services in a partnership that will make Ibex's AI-enabled decision support tools accessible to pathology laboratories.
Ibex's AI tools support clinicians in breast and prostate cancer diagnosis through its Navify digital pathology software platform.
Ibex highlighted that its AI algorithms help clinicians diagnose breast and prostate biopsies and provide efficient, accurate, and timely cancer diagnosis. They also support case prioritization, determine the cancer grading and subtype, and identify noncancerous features, the company added. This information is displayed in the Navify platform.
Roche's technology and Ibex's algorithms will operate on Amazon Web Services.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
